Ray Co., Ltd. (KOSDAQ:228670)
6,410.00
-210.00 (-3.17%)
Sep 19, 2025, 3:30 PM KST
Ray Co., Ltd. Revenue
Ray Co., Ltd. had revenue of 27.51B KRW in the quarter ending June 30, 2025, with 11.16% growth. This brings the company's revenue in the last twelve months to 89.70B, down -30.26% year-over-year. In the year 2024, Ray Co., Ltd. had annual revenue of 79.84B, down -45.27%.
Revenue (ttm)
89.70B
Revenue Growth
-30.26%
P/S Ratio
1.11
Revenue / Employee
509.67M
Employees
176
Market Cap
100.01B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 79.84B | -66.04B | -45.27% |
Dec 31, 2023 | 145.88B | 16.88B | 13.09% |
Dec 31, 2022 | 129.00B | 38.66B | 42.80% |
Dec 31, 2021 | 90.34B | 35.13B | 63.64% |
Dec 31, 2020 | 55.20B | -17.90B | -24.49% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Samsung Biologics | 5,031.69B |
Celltrion | 3,748.95B |
ALTEOGEN | 158.06B |
Yuhan | 2,165.44B |
SK Biopharmaceuticals | 620.28B |
Peptron | 5.18B |
PharmaResearch | 449.81B |
ABL Bio | 94.93B |